Belimumab and the clinical data

Current Rheumatology Reports

Volumn 14, Issue 4, 2012, Pages 310-317

  Shum, Katrina ^a   Askanase, Anca ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Belimumab; Benlysta; Clinical data; Clinical trials; Efficacy; FDA; Lupus; Phase 2; Phase 3; Safety; SELENA SLEDAI; SLE; Systemic lupus erythematosus; Treatment; US Food and Drug Administration

Indexed keywords

BELIMUMAB; PLACEBO; PREDNISONE;

ARTHRALGIA; ARTHRITIS; BACKACHE; BRONCHITIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INFLUENZA; INSOMNIA; NAUSEA; PRACTICE GUIDELINE; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SINUSITIS; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84864842488     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0264-4     Document Type: Review

References (27)

1. Urowitz M, Gladman D, Ibanez D, et al. Evolution of disease burden over 5 years in a multicentre inception SLE cohort. Arthritis Care Res (Hoboken) 2011.
2. Lim SS, Drenkard C, McCune WJ, et al. Population-based lupus registries: advancing our epidemiologic understanding. Arthritis Rheum. 2009;61(10):1462-6.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythema-tosus. Arthritis Rheum. 1997;40(9):1725.
4. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7.
5. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53(6):424-32.
6. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A longterm, prospective study. Arthritis Rheum. 1990;33(5):634-43.
7. Askanase AD, Wallace DJ, Weisman MH, et al. Use of pharmaco-genetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(1):89-95.
8. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythemato-sus. J Rheumatol. 1999;26(6):1275-9.
9. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219-28.
10. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253-65.
11. Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol. 2010;42(4):543-50.
12. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995-9.
13. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260-3.
14. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293(5537):2108-11.
15. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6-10.
16. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-9.
17. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.
18. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimu-mab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-78.
19. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143-51.
20. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimu-mab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-10.
21. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-30.
22. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-31.
23. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012.
24. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012.
25. Chowdhury BA. FDA briefing information BLA 125370; Ben-lysta (belimumab), A.A. Committee, Editor. 2010.
26. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-7.
27. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52(5):1481-90.